November 2014


In this Supplement

The Rise of Peripheral Drug Elution

How to incorporate drug-coated balloons and drug-eluting stents into your practice.


US Supplement


Download a PDF of this supplement

Drug Elution, Data, and Decisions

What the data tell us about how to integrate drug-eluting technology into our daily practice.

By Gary Ansel, MD, and John A. Phillips, MD

An Overview of Superficial Femoral Artery Stenting

The history, data, and latest advancements in stenting of the SFA and popliteal arteries.

By John R. Laird, MD, and Ehrin J. Armstrong, MD

Zilver PTX for Simple and Challenging Lesions

How I integrate this versatile tool into my lower extremity practice.

By William A. Gray, MD

DCBs in the United States

The use of drug-coated balloons is creating a paradigm shift in the treatment of peripheral arterial disease by preventing restenosis and leaving nothing behind.

By George L. Adams, MD, MHS, and O Jesse Mendes, BA

DES and DEB Use in Europe

As devices develop and longer follow-up data become available, one thing is certain: It’s a drug-eluting world, all right.

By Konstantinos Katsanos, MSc, MD, PhD, EBIR

The Costs and Benefits of Medical Innovation

Looking beyond prices and assessing the true value of new technologies.

By Louis L. Nguyen, MD, MBA, MPH, and Rebecca E. Scully, MD

DES Versus Bypass for Femoropopliteal Disease

Should the current data on drug-eluting devices cause surgeons to reconsider when to use bypass?

By Marc Bosiers, MD, and Koen Deloose, MD

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.